Role of surrogate end points in the evaluation of drugs for heart failure
- 31 October 1993
- journal article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 22 (4) , A179-A184
- https://doi.org/10.1016/0735-1097(93)90487-l
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.Circulation, 1992
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1991
- A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.Circulation, 1990
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind menJournal of the American College of Cardiology, 1987
- Six minute walking test for assessing exercise capacity in chronic heart failure.BMJ, 1986
- Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial.Circulation, 1984